| Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (NCT01461915) | Jazz Pharmaceuticals | 2011-11-01 |
| Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (NCT01494506) | Merrimack Pharmaceuticals | 2011-11-01 |
| Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (NCT01523457) | Yale University | 2011-10-01 |
| Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer (NCT01417000) | Aduro Biotech, Inc. | 2011-09-21 |
| A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma (NCT01410968) | Carolyn Britten | 2011-08-01 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (NCT01231347) | NantCell, Inc. | 2011-04-07 |
| Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer (NCT01303029) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2011-02-01 |
| ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (NCT01489865) | Georgetown University | 2011-01-03 |
| Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer (NCT01272791) | Peregrine Pharmaceuticals | 2011-01-01 |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (NCT01088815) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-09-17 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (NCT01174121) | National Cancer Institute (NCI) | 2010-08-26 |
| Metformin Combined With Chemotherapy for Pancreatic Cancer (NCT01210911) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2010-08-01 |
| A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer (NCT01130142) | Infinity Pharmaceuticals, Inc. | 2010-04-01 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver (NCT00986661) | Provectus Biopharmaceuticals, Inc. | 2009-10-01 |
| Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer (NCT01077986) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2009-08-01 |
| Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer (NCT00954525) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2009-07-01 |
| Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer (NCT00922896) | Gyeongsang National University Hospital | 2009-06-01 |
| A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer (NCT01028495) | Rexahn Pharmaceuticals, Inc. | 2009-05-01 |
| Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas (NCT00844649) | Celgene | 2009-03-01 |
| A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer (NCT00726037) | Loyola University | 2008-10-01 |
| Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer (NCT00761345) | Fox Chase Cancer Center | 2008-09-01 |
| APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer (NCT00709826) | Tragara Pharmaceuticals, Inc. | 2008-08-01 |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (NCT00630552) | NantCell, Inc. | 2007-06-01 |
| BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer (NCT00447122) | Brown University | 2007-03-01 |
| Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer (NCT00786006) | Asan Medical Center | 2007-03-01 |
| A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer (NCT00383149) | R-Pharm | 2007-01-01 |
| Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer (NCT00398086) | Celgene | 2006-11-01 |
| Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer (NCT00868114) | Leo W. Jenkins Cancer Center | 2006-07-01 |
| A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema (NCT00439179) | Brown University | 2006-07-01 |
| Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer (NCT00326911) | Eli Lilly and Company | 2006-05-01 |
| Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma (NCT00744640) | University Hospital, Basel, Switzerland | 2005-10-01 |
| Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer (NCT00222469) | University of Oklahoma | 2005-08-01 |
| The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib (NCT01608841) | Taipei Veterans General Hospital, Taiwan | 2005-07-01 |
| Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer (NCT00652054) | Taiho Oncology, Inc. | 2005-06-01 |
| Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) (NCT00996333) | Columbia University | 2003-06-01 |
| A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer (NCT00245362) | Cell Genesys | 2002-06-01 |
| Gemcitabine (GFF) in Patients With Pancreatic Cancer (NCT00919282) | CONKO-Studiengruppe | 1997-09-01 |